CytomX Therapeutics (CTMX) Projected to Post Quarterly Earnings on Thursday

CytomX Therapeutics (NASDAQ:CTMX) will likely be announcing its earnings results before the market opens on Thursday, March 6th. Analysts expect the company to announce earnings of ($0.23) per share and revenue of $13.53 million for the quarter. Individual interested in registering for the company’s earnings conference call can do so using this link.

CytomX Therapeutics Stock Up 0.3 %

NASDAQ CTMX opened at $0.68 on Friday. CytomX Therapeutics has a 52 week low of $0.66 and a 52 week high of $5.85. The business’s fifty day simple moving average is $0.89 and its 200-day simple moving average is $1.04. The firm has a market cap of $53.00 million, a PE ratio of 3.98 and a beta of 1.01.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reiterated a “neutral” rating on shares of CytomX Therapeutics in a report on Tuesday, January 7th. Four equities research analysts have rated the stock with a hold rating and three have given a buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average price target of $5.77.

CytomX Therapeutics Company Profile

CytomX Therapeutics, Inc, an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology.